Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Terminated 3Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Conditions

Leiomyoma 4Menorrhagia 2

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Has results × vilaprisan × Clear all
NCT03194646 2025-07-28

ASTEROID 6

Bayer

Phase 3 Terminated
1,272 enrolled 16 charts

Leiomyoma

NCT03400943 2023-05-03

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)

Bayer

Phase 3 Terminated
93 enrolled 19 charts

Leiomyoma, Menorrhagia

NCT03400956 2022-06-30

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)

Bayer

Phase 3 Terminated
103 enrolled 18 charts

Leiomyoma, Menorrhagia

NCT02131662 2017-12-08

ASTEROID 1

Bayer

Phase 2 Completed
309 enrolled 24 charts

Leiomyoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡